SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Reddit Emerges as a Major Winner in the Shift to AI-Powered Search 
Trump Blocks HieFo’s Emcore Chip Assets Deal Over National Security Concerns 
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 
NextEra Energy Stock Rises After Reaffirming Earnings and Dividend Growth Outlook 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Bain Capital Moves to Acquire Majority Stake in Echo Marketing 
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
 Securities Case - EconoTimes)
NEW YORK, April 01, 2016 -- Scott + Scott, Attorneys at Law, LLP, a global investor rights law firm, reminds investors that April 4, 2016 is the last day to file lead plaintiff papers in the securities lawsuit against Insys Therapeutics, Inc. (NASDAQ:INSY). Insys investors are encouraged to contact Scott + Scott at (866) 326-5057 or email [email protected] to discuss their legal rights.
About the Lawsuit
The complaint alleges that, throughout the Class Period, Defendants issued materially false and misleading statements to investors and/or failed to disclose that: (1) Insys was engaged in the illegal and improper off-labeling marketing of Subsys; (2) certain Insys employees were complicit in an illegal kickback scheme operated for the purpose of increasing prescriptions of Subsys; and (3) as a result, Insys’ financial statements were materially false and misleading at all relevant times. After a series of news articles revealed that the Company had allegedly engaged in illegal and improper off-label marketing of Subsys, the Company’s shares fell dramatically in price, thereby injuring investors.
What you can do
If you purchased shares of Insys stock, you may have legal claims against the Company. If you want to discuss filing lead plaintiff papers, or have questions about your legal rights, please contact Geoffrey M. Johnson, Esq. or Joseph Halloran, Esq. by telephone at (866) 326-5057 or by email at [email protected] or [email protected].
About Scott + Scott, Attorneys at Law, LLP
Scott + Scott has significant experience prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States. The firm has offices in New York, London, Connecticut, California and Ohio. Please visit www.scott-scott.com for more information about the firm.
CONTACT: Scott + Scott, Attorneys at Law, LLP Geoffrey M. Johnson, Esq. Joseph Halloran, Esq. (216) 229-6088, toll-free (866) 326-5057 [email protected] [email protected]
